# US 2026/0097012 A1 · Compositions and methods for treating graft-related arrhythmia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097012 A1
- Document ID: US20260097012A1
- Status: Published application
- Kind: A1
- Application number: 19/115,880
- Filed: 2023-09-27
- Published: 2026-04-09
- Earliest claimed: 2022-09-28
- Assignees: BlueRock Therapeutics LP
- Applicants: BlueRock Therapeutics LP
- Inventors: Ibrahim Domian; Rocco Romagnuolo
- Web page: https://patentgrep.com/patent/US20260097012A1

## CPC

- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61P 9/06: Antiarrhythmics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods of treating or preventing an arrhythmia in a cardiac graft patient, wherein the method comprises administering combinations of anti-arrhythmic agents (e.g., amiodarone, metoprolol, ivabradine, and/or mexiletine) to the subject in need thereof.

## Claims

### Claim 1

A method comprising administering two or more of:
amiodarone,
metoprolol,
ivabradine, and
mexiletine,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
to a subject in need thereof, wherein the subject is in need of or has received a cardiac graft.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method comprises administering two or more of:
amiodarone,
metoprolol, and
ivabradine,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
to a subject in need thereof, wherein the subject is in need of or has received a cardiac graft.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the method comprises administering
amiodarone, and
ivabradine,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the method does not comprise administering amiodarone, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, to the subject in need thereof.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the method does not comprise administering ivabradine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, to the subject in need thereof.

### Claim 6 (depends on 1, 2, 3)

The method of any one of claims 1-3, comprising administering each of
amiodarone,
metoprolol,
verapamil, and
ivabradine, and
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
to the subject in need thereof.

### Claim 7 (depends on 1, 2, 3)

The method of any one of claim 1-3, or 6, further comprising administering lidocaine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, to the subject in need thereof.

### Claim 8 (depends on 1, 2, 3)

The method of any one of claim 1-3, or 6-7, further comprising administering procainamide, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, to the subject in need thereof.

### Claim 9 (depends on 1, 2, 3)

The method of any one of claim 1-3, or 6-8, further comprising administering verapamil, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, to the subject in need thereof.

### Claim 10 (depends on 1, 2, 3)

The method of any one of claim 1-3, or 6-9, comprising administering each of
amiodarone,
metoprolol,
verapamil,
ivabradine, and
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
to the subject in need thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein each of amiodarone, metoprolol, verapamil, ivabradine, lidocaine, and procainamide, optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, are administered at least once per day to the subject in need thereof.

### Claim 12 (depends on 1, 2, 3)

The method of any one of claims 1-3, comprising administering each of amiodarone, metoprolol, ivabradine, and mexiletine, optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, to the subject in need thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein each of each of amiodarone, metoprolol, ivabradine, and mexiletine, optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, are administered at least once per day to the subject in need thereof.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, comprising: administering two or more of
metoprolol,
ivabradine, and/or
mexiletine,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
to the subject in need thereof.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, comprising administering two or more of
amiodarone,
metoprolol, and/or
mexiletine,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
to the subject in need thereof.

### Claim 16 (depends on 12, 13, 14, 15)

The method of any one of claims 12-15, comprising administering each of
amiodarone,
mexiletine,
verapamil,
ivabradine,
lidocaine, and
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
to the subject in need thereof.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the subject is at risk of or suffers from arrhythmia.

### Claim 18 (depends on 17)

The method of claim 17, wherein the arrhythmia is tachycardia.

### Claim 19 (depends on 17, 18)

The method of claim 17 or 18, wherein the arrhythmia is ventricular tachycardia.

### Claim 20 (depends on 17, 18, 19)

The method of any one of claims 17-19, wherein the arrhythmia is caused by the cardiac graft or at least in part by the cardiac graft.

### Claim 21 (depends on 17, 18, 19, 20)

The method of any one of claims 17-20, wherein the arrhythmia occurs after the cardiac graft.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any of claims 1-21, wherein the
amiodarone,
metoprolol,
ivabradine,
mexiletine,
lidocaine,
verapamil, and/or
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
are administered concurrent with administration of the cardiac graft.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any of claims 1-22, wherein the one or more of
amiodarone,
metoprolol,
ivabradine,
mexiletine,
lidocaine,
verapamil, and/or
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
are administered subsequent to administration of the cardiac graft.

### Claim 24 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any of claims 12-23, wherein the
amiodarone,
metoprolol,
ivabradine,
mexiletine,
lidocaine,
verapamil, and/or
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
are administered prior to administration of the cardiac graft.

### Claim 25 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 12-24, wherein the
amiodarone,
metoprolol,
ivabradine,
mexiletine,
lidocaine,
verapamil, and/or
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
are administered within about 7 days, or about 6 days, or about 5 days, or about 4 days, or about 3 days, or about 2 days, or about 1 days, or about 24 hours, or about 20 hours, or about 18 hours, or about 16 hours, or about 14 hours, or about 12 hours, or about 10 hours, or about 8 hours, or about 6 hours, or about 5 hours, or about 4 hours, or about 3 hours, or about 2 hours, or about 1 hour, or about 50 minutes, or about 40 minutes, or about 30 minutes, or about 20 minutes, or about 10 minutes, or about 5 minutes, or about 4 minutes, or about 3 minutes, or about 2 minutes, or about 1 minute of administration of the cardiac graft.

### Claim 26 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 12-24, wherein the
amiodarone,
metoprolol,
ivabradine,
mexiletine,
lidocaine,
verapamil, and/or
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
are administered within between 1 and 3 minutes, between 3 and 10 minutes, between 10 and 30 minutes, between 30 and 60 minutes, between 1 and 3 hours, between 3 and 6 hours, between 6 and 8 hours, between 8 and 12 hours, between 12 and 18 hours, between 18 and 24 hours, between 1 and 2 days, between 2 and 3 days, between 3 and 5 days, or between 5 and 7 days, inclusive.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the method further comprises an additional administration of mexiletine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, conducted 24 or more hours subsequent to a first administration of mexiletine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the amiodarone, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof is administered parenterally.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1-28, wherein the amiodarone, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered orally.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the metoprolol, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered parenterally.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the metoprolol, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered orally.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the metoprolol, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is in an extended-release form.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1-32, wherein the ivabradine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered parenterally.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-33, wherein the ivabradine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered orally.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the mexiletine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered parenterally.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein the mexiletine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered orally.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein the lidocaine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered parenterally.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1-37, wherein the lidocaine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered intravenously.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1-38, wherein the lidocaine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered orally.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 1-39, wherein the procainamide, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered parenterally.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 1-40, wherein the procainamide, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered orally.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 1-41, wherein the procainamide, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered parenterally.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 1-42, wherein the procainamide, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is administered orally.

### Claim 44 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 28-43, wherein the parenteral administration is intravenous administration.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the dose of amiodarone, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is 100-1400 mg per day.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the dose of amiodarone, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is about 800 mg per day.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the dose of amiodarone, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is about 1200 mg per day.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, wherein the dose of metoprolol, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is 75-125 mg per day.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, wherein the dose of metoprolol, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is about 100 mg per day.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 1-49, wherein the dose of ivabradine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is 5-20 mg per day.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 1-49, wherein the dose of ivabradine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is about 10 mg per day.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 1-51, wherein the dose of mexiletine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is 100-500 mg per day.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 1-51, wherein the dose of mexiletine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is about 200-400 mg per day.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 1-51, wherein the dose of mexiletine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is about 200 mg per day.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 1-51, wherein the dose of mexiletine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is about 400 mg per day.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 1-55, wherein the dose of verapamil, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is 150-500 mg per day.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 1-55, wherein the dose of verapamil, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, is about 240-360 mg per day.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 1-57, wherein the dose of amiodarone, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, administered is about 400 mg twice a day.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 1-57, wherein the dose of amiodarone, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, administered is about 600 mg twice a day.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the dose of metoprolol, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, administered is about 50 mg twice a day.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 1-60, wherein the dose of ivabradine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, administered is about 5 mg twice a day.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 1-61, wherein the dose of mexiletine, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, administered is about 100-200 mg twice a day.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 1-62, wherein the dose of verapamil, or an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof, administered is about 80-120 mg three times a day.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claim 1-63, wherein the
amiodarone,
metoprolol,
ivabradine,
mexiletine,
lidocaine,
verapamil, and/or
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
are administered to the subject to maintain a resting heart rate of less than or equal to 150 beats per minute.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 1-64, wherein the
amiodarone,
metoprolol,
ivabradine,
mexiletine,
lidocaine,
verapamil, and/or
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
are administered to the subject at least once per day until the arrhythmia has ceased.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 1-65, wherein the
amiodarone,
metoprolol,
ivabradine,
mexiletine,
lidocaine,
verapamil, and/or
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof,
are administered to the subject for about 1-12 weeks, or about 1-8 weeks, or about 1-4 weeks after the cardiac graft is administered.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 1-66, wherein the cardiac graft comprises cardiomyocytes.

### Claim 68 (depends on 67)

The method of claim 67, wherein the cardiomyocytes are ventricular cardiomyocytes.

### Claim 69 (depends on 68)

The method of claim 68, wherein the ventricular cardiomyocytes are immature cardiomyocytes.

### Claim 70 (depends on 69)

The method of claim 69, wherein the ventricular cardiomyocytes are mature cardiomyocytes.

### Claim 71 (depends on 67, 68, 69, 70)

The method of any one of claims 67-70, wherein the cardiomyocytes are made from induced pluripotent stem cells.

### Claim 72 (depends on 71)

The method of claim 71, comprising administering the cardiomyocytes to the subject in an amount effective to treat a cardiovascular disease, disorder, or symptom thereof.

### Claim 73 (depends on 72)

The method of claim 72, wherein the effective amount of cardiomyocytes is an amount effective to treat heart failure.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 1-73, wherein the method further comprises administering to the subject in need thereof one or more immunosuppressants.

### Claim 75 (depends on 74)

The method of claim 74, wherein at least one of the immunosuppressants is cyclosporin A, methylprednisolone, or abatacept, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof.

### Claim 76 (depends on 74, 75)

The method of claim 74 or 75, wherein at least one of the immunosuppressants is administered prior to, e.g., between 1 and 3 hours, between 3 and 6 hours, between 6 and 12 hours, between 12 and 24 hours, between 1 and 2 days, between 2 and 3 days, between 3 and 5 days, between 5 and 7 days, between 7 and 10 days, or between 10 and 14 days, inclusive, prior to the administration of the cardiac graft.

### Claim 77 (depends on 74, 75)

The method of claim 74 or 75, wherein at least one of the immunosuppressants is administered subsequent to, e.g., between 1 and 3 hours, between 3 and 6 hours, between 6 and 12 hours, between 12 and 24 hours, between 1 and 2 days, between 2 and 4 days, between 4 and 7 days, between 1 and 2 weeks, between 2 and 4 weeks, or between 1 and 2 months, inclusive, subsequent to the administration of the cardiac graft.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 1-77 further comprising using or implanting a mechanical circulatory support on or to the subject.

### Claim 79 (depends on 78)

The method of claim 78, wherein the mechanical circulatory support is a left ventricular assist device, a right ventricular assist device, a bi ventricular assist device, extra corporeal membrane oxygenation, or implantable cardiac defibrillator, or a combination thereof.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 1-79, wherein the subject is at risk of or suffers from a cardiovascular disease.

### Claim 81 (depends on 80)

The method of claim 80, wherein the cardiovascular disease is ischemic cardiomyopathy, dilated cardiomyopathy, or heart failure associated with prior myocardial infarction.

### Claim 82 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method of any one of claims 1-81, wherein the subject is at risk of or has suffered from myocardial infarction.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The method of any one of claims 1-82, wherein the subject suffers from a cardiac birth defect or congenital heart disease, optionally hypoplastic left heart syndrome.

### Claim 84

A pharmaceutical composition comprising two or more of:
amiodarone,
metoprolol,
ivabradine,
mexiletine,
lidocaine,
verapamil, and
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof; and
optionally a pharmaceutically acceptable excipient.

### Claim 85

A kit comprising:
(1) two or more of:
amiodarone,
metoprolol,
ivabradine, and/or
mexiletine,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof; and
(2) instructions for administering (1) to treat or prevent arrhythmia in a subject in need thereof.

### Claim 86 (depends on 85)

The kit of claim 85, further comprising:
(3) lidocaine,
verapamil, and/or
procainamide,
optionally each of which independently comprises an analog or derivative thereof, or a pharmaceutically acceptable salt, isotopically labeled compound, tautomer, stereoisomer, solvate, tautomer, hydrate, polymorph, co-crystal, or prodrug thereof; and
(4) instructions for administering (3) to treat or prevent arrhythmia in a subject in need thereof.

### Claim 87 (depends on 85, 86)

The kit of claim 85 or 86, wherein the subject in need thereof is in need of or has received a cardiac graft.
